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ABSTRAK
Tujuan: untuk mengevaluasi efek analgesik, efek samping, dan keamanan dari obat setelah prosedur endoskopi 
di bidang urologi. Metode: 80 pasien yang menjalani operasi endoskopi di Rumah Sakit Kardinah, Tegal sejak 
Juni sampai Juli 2015 dibagi jadi empat kelompok. Kelompok eksperimental diberikan analgesik selama 4 hari, 
(A) asam pipemidat 400 mg bid, atau (B) phenazopyridine 200 mb tid, atau (C) diklofenak 50 mg bid, dan (D) 
plasebo tid. Efek analgesik dinilai dengan Visual Analog Scale (VAS). Hubungan antar variabel dinilai dengan 
menggunakan Cramers V dan Kruskall Wallis. Hasil: prosedur endoskopi urologi terdiri dari 30 pasien menjalani 
URS, 6 pasien litotripsi, 17 pasien TURP, 24 pasien pengangkatan dj stent, dan 3 pasien sistoskopi. Rerata usia 
kelompok A, B, C, dan D adalah 50.1 (13.7), 50.7 (14.8), 49.1 (13.4), dan 49.6 (14.3) tahun, dan rerata lama 
followup adalah 7 hari. Nilai VAS dari seluruh kelompok eksperimental lebih rendah dari kelompok kontrol pada 
hari pertama sampai hari ke tujuh setelah prosedur endoskopi (p<0.05). Pada kelompok eksperimental, tidak 
terdapat perbedaan antara kelompok B dan C (p>0.05). Kelompok A memperlihatkan efek analgesik yang lebih 
baik daripada B dan C (p<0.05). Tidak didapatkan efek samping yang serius pada seluruh kasus. Kesimpulan: 
penggunaan analgesik oral efektif untuk meredakan nyeri setelah operasi endoskopi di bidang urologi. Asam 
pipemidat memiliki efek analgesik yang superior.
Kata kunci: asam pipemidat, phenazopyridine, diklofenak, endoskopik , visual analog scale.
ABSTRACT
Aim: to evaluate the analgesic effect, the side effects and the safety of analgesics following endoscopic 
urological procedure. Methods: eighty patients who underwent endoscopic urological surgery at Kardinah 
Hospital, Tegal from June to July 2015 were divided into four groups. The experimental group was administered 
analgesic for 4 days pipemidic acid (A) 400 mg bid, or phenazopyridine (B) 200 mg tid, or sodium diclofenac 
(C) 50 mg bid and the control (D) group was administered placebo tid for 4 days. The analgesic effects were 
assessed using Visual Analog Scale (VAS). Association between variables was assessed using Cramers V and 
Kruskall Wallis. Results: the endoscopic urological procedures consisted of 30 patients for URS, 6 patients for 
lithotripsy, 17 patients for TURP, 24 patients for removal JJ stent and 3 patients for cystoscopy. The mean age 
of group A, B, C and D (control) was 50.1 (13.7), 50.7 (14.8), 49.1 (13.4), and 49.6 (14.3) years, respectively, 
and follow-up period was 7 days. The VAS score in all experimental groups was less than control group on 
day 1 to 7 following endoscopic urological procedures (p<0.05). In the experimental group, there was no 
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difference between groups B and C (p>0.05). Group A demonstrated a more favourable analgesic effect than B 
and C (p<0.05). No serious side effects were detected in any of the cases. Conclusion: we conclude that oral 
analgesics are effective for pain relief following endoscopic urological surgery. Pipemidic acid was found to 
have a superior analgesic effect than phenazopyridine HCl and sodium diclofenac.
Keywords: pipemidic acid, phenazopyridine, sodium diclofenac, endoscopic urology, visual analog scale.
INTRODUCTION
Pain is a common symptom following 
endoscopic urological surgery, and the need for 
effective pain management is a major concern. In 
general, regional or local anaesthesia demonstrates 
distinct advantages and disadvantages in terms of 
postoperative morbidity.1,2 Therefore, general or 
regional anesthesia has been replaced by opioids, 
sedatives, non-steroidal anti-inflammatory drugs 
(NSIADs), and topical anesthetics for pain 
management.3,4 The ideal postoperative analgesic 
treatment should provide rapid and effective 
pain relief, offer a low incidence of adverse 
effects and result in a minimal impact on organ 
systems with no significant interaction with 
other pharmacological agents.1 The mechanism 
of acute pain following endoscopic urological 
surgery remains unclear. Acute postoperative 
pain is mainly associated with the operation itself 
and the duration of operation time.5
Until now, many urologists have not yet 
studied the outcome of acute post-operative pain 
which the patients perceive as a serious problem 
and which accompanies most postoperative 
complications.5 In addition to NSAIDs, there 
are several drugs known as anti-microbial 
and uroseptic that have an analgesic effect, 
such as phenazopyridine hcl and pipemidic 
acid.6–8 Based on the degree of pain, urological 
procedures, such as extracorporeal shock wave 
lithotripsy (ESWL), endoscopic urological 
surgery (transurethral, endoscopic percutaneous) 
and trans-vaginal surgery are still included in the 
category of mild pain following surgery.9
Phenazopyridine relieves pain associated 
with bladder spasms and postoperative ureteral 
stent or in-dwelling urinary catheter discomfort.4,6 
Pipemidic acid is an anti-microbial group that 
is used as a urinary antiseptic and reduces pain 
caused by an acute tract infection.7,10,11 The 
analgesic effect of pipemidic acid following 
endoscopic urological surgery is controversial 
and, to date, there are no relevant study reports 
to support the claim. The analgesic effect might 
be caused by optimization of a pipemidic acid 
autotaxin inhibitor.12–15 Non-steroidal anti-
inflammatory drugs (NSAIDs) are commonly 
used for their potent antipyretic and analgesic 
effects. These drugs reduce pain following 
surgery by preventing synthesis and release of 
prostaglandins at the site of surgical trauma by 
inhibition of cyclo-oxygenase-2 (COX-2).1
The clinical indication and analgetic effect 
of pipemidic acid, phenazopyridine and sodium 
dicofenac remain unclear. The purpose of this 
prospective, randomized study was to compare 
the effectiveness of analgesia and side-effects of 
pipemidic acid, phenazopyridine hcl and sodium 




This study was a prospective, randomized, 
double-blind, placebo-controlled trial. The 
study compared the analgesic effects following 
endoscopic urological surgery. Pain perception 
was assessed from the first day until the seventh 
day following surgery. Analgesic drugs were 
administered for 4 days following surgery. 
The analgesic effects were assessed using the 
Visual Analog Scale (VAS). The eligibility 
criteria of subject was age ≥17 years old who 
underwent endoscopic urological surgery, 
such as transurethral resection transurethral 
of prostate (TURP), ureterorenoscopy (URS), 
lithotripsy of bladder stone, removal double-J 
stent and cystoscopy. No history was presented 
of psychotic mental illness, organic psychiatric 
conditions and other mental illnesses, of severe 
pain-induced illnesses and malignancy. The 
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patient underwent open surgery conversion after 
exclusion of endoscopic urological surgery. The 
study was initiated after obtaining the approval 
of the Institutional Ethics Committee Kardinah 
Hospital. Ref: 071/008/2015.
Intervention
The patients who underwent endoscopic 
urological surgery (transurethral resection of 
prostate (TURP), lithotripsy of bladder stone, 
ureterorenoscopy (URS), removal JJ stent and 
cystoscopy) at Kardinah Hospital, Tegal from 
June 2015 to July 2015 were divided into four 
groups. The experimental groups (A, B and C) 
consisted of 20 patients in each group while the 
control group (D) consisted of 20 patients. The 
experimental group was administered antibiotics, 
anticoagulant and analgetic medication. In group 
A, patients were administered pipemidic acid 
400 mg bid for 4 days. In group B, patients were 
administered phenazopyridine 200 mg tid for 4 
days. In group C, 50 mg of sodium diclofenac 
was applied twice a day for 4 days. Control group 
D was administered antibiotics, anticoagulant 
and placebo medication tid for 4 days. All groups 
were randomized by block random system. 
All patients were remained consistant for the 
duration of this study. The analgesic effects were 
assessed using the Visual Analog Scale (VAS).
Statistical Analysis
Age, gender, day of catheterization, operation 
time, hospitalization, patient satisfaction, adverse 
events, patient complaints and VAS scale for 
each patient were recorded. Statistical analysis 
was recorded using one way ANOVA, Kruskal 
Wallis; Cramers V, Mann U Whitney, and results 
were compared between the four groups. A P 
value of less than 0.05 was considered to be 
statistically significant.
RESULTS
Patients characteristics are summarized in 
Table 1. The average age of the 80 patients (50 
males and 30 females) was 49.9 (13.8) years old. 
The endoscopic urological procedures included 
30 patients for URS, 6 patients for lithotripsy of 
bladder stone, 17 patients for TURP, 24 patients 
for removal JJ stent and 3 patients for cystoscopy. 
(Figure 1) The overall postoperative VAS scale 
following endoscopic urological surgery was 
summarized in Table 2 and 3.
Table 1. Subject’s characteristics
Variables Overall Pipemidic Acid Phenazopyridine HCl Sodium Diclofenac Placebo




1.4  (1.5) 1.3 (1.5) 1.4 (1.5) 1.5 (1.5) 1.4 (1.5)
Operation time, 
mean (SD) 33.5 (21.6) 33.3 (25) 35.1 (21.2) 34 (21) 31.5 (20.1)
Hospitalization, 
mean (SD) 1.5 (1.5) 1.4 (1.5) 1.5 (1.7) 1.6 (1.5) 1.5 (1.5)
Diagnosis, n (%)
 - Ureteral stone 29 (36.3) 7 (35) 7 (35) 8 (40) 7 (35)
 - Ureteral stenosis 1 (1.3) 0 (0) 1 (5) 0 (0) 0 (0)
 - Bladder stone 6 (7.5) 2 (10) 1 (5) 1 (5) 1 (5)
 - Benign prostate 
hyperplasia 
(BPH)
17 (21.3) 4 (20) 4 (20) 5 (25) 4 (20)
 - JJ Stent in situ 24 (30) 7 (35) 6 (30) 5 (25) 6 (30)
 - Voiding 
dysfunction 3 (3.8) 0 (0) 1 (5) 1 (5) 1 (5)
Gender, n (%)
 - Male 50 (62.5) 12 (60) 11 (55) 14 (70) 13 (65)
 - Female 30 (37.5) 8 (40) 9 (45) 6 (30) 7 (35)
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Table 1. Subject’s characteristics
Variables Overall Pipemidic Acid Phenazopyridine HCl Sodium Diclofenac Placebo
Management, n (%)
 - URS/Lithotripsy 36 (45) 9 (45) 9 (45) 9 (45) 9 (45)
 - TURP 17 (21.3) 4 (20) 4 (20) 5 (25) 4 (20)
 - DJ stent removal/ 
Cystoscopy 27 (33.7) 7 (35) 7 (35) 6 (30) 7 (35)
Catheterization, n (%)
 - Yes 56 (70) 13 (65) 14 (70) 15 (75) 14 (70)
 - No 24 (30) 7 (35) 6 (30) 5 (25) 6 (30)
JJ Stent insertion, 
n (%)
 - Yes 14 (17.5) 3 (15) 3 (15) 4 (20) 4 (20)
 - No 66 (82.5) 17 (85) 17 (85) 16 (20) 16 (20)
Patient satisfaction, n (%)
 - Yes 69 (86.3) 20 (100) 19 (95) 18 (90) 13 (65)
 - No 11 (13.7) 0 (0) 1 (5) 2 (10) 7 (35)
Urinalysis, mean (SD) 
 - Ph 5.9 (0.8) 5.8 (0.7) 5.8 (0.7) 6.3 (0.9) 6  (0.6)
 - Specific gravity 1.01 (0.007) 1.013 (0.006) 1.015 (0.008) 1.016 (0.008) 1.015 (0.007)
Erithrocituria, n (%)
 - Yes 58 (72.5) 14 (70) 13 (65) 16 (80) 15 (75)
 - No 22 (27.5) 6 (30) 7 (35) 4 (20) 5 (25)
Leucocyturia, n (%)
 - Yes 63 (78.8) 17 (85) 17 (85) 14 (70) 15 (75)
 - No 17 (21.2) 3 (15) 3 (15) 6 (30) 5 (25)
80 patients who underwent endoscopic urology surgery (30 patients URS, 6 patients lithotripsy, 17
patients TURP, 24 patients removal JJ stent and 3 patients cystoscopy).
Randomization, Double blind
20 were assigned to be
grup A (Sodium





20 were assigned to be






20 were assigned to be
grup C (phenazopyri -
dine HCl 200 mg tid)




20 were assigned to be
grup A (Placebo tid)




Figure 1. Consort flow diagram of the current randomized controlled trial
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The comparison of median age of groups 
1, 2, 3 and 4 were 50.1, 50.7, 49.1 and 49.6 
years, respectively, compared with 44.98 years 
in group 2 (p=0.05). Leukocyturia was found in 
17 patients in group 1, 17 patients in group 2, 
14 patients in group 3 and 15 patients in group 
4 (p=0.57). The most common diagnosis was 
ureteral stones in 29 patients. Catheterization 
and double-J stent insertion were undertaken in 
56 and 14 patients, respectively.
Decrease of VAS scale following endoscopic 
urological surgery was statistically significant 
from day one until day seven (p<0.05). However, 
if we compare the various methods of endoscopic 
urological surgery, the decrease of VAS scale 
was only statistically significant on day one 
(p=0.014), but not statistically significant during 
the other days (p>0.05). In the experimental 
group, there was no difference between group 
B and C (p>0.05). Group A demonstrated a 
better analgesic effect than B and C (p<0.05). 
(Table 5 and Figure 2) No serious side effects 
were detected in any of the cases (Table 4). 
Eleven patients complained of severe acute 
postoperative pain with VAS 7-10 (one patient 
in group 1, 3 patients in group 2, 3 patients in 
group 3 and 4 patients in group 4). This was 
optimally controlled with ketoprofen 50 mg 
suppositories of non-steroidal anti-inflammatory 
drugs (NSAIDs).
DISCUSSION
Major advancements have been made in 
recent times in urological treatments which 
constituted the majority of urological conditions. 
In the past, treatment involved mainly invasive 
procedures. In recent years, non-invasive 
procedures, such as endourological surgery, 
have been made available.5 Pain management is 
a common and complex issue for the urologist. 
Unrelieved pain is a major medical problem. 
In the end of the 1990s, the physiological 
and psychological consequences of acute and 
chronic pain became well-recognized16, and pain 
management during transurethral procedures 
is now well established.1,2 However, many 
urologists have not yet studied the relief of 
acute postoperative pain following endoscopic 












mean (SD) p value
Day 1 5.3 (2.6) 3.2 (1.8) 5.9 (2.2) 5.4 (2.8) 6.7 (2.2) <0.001
Day 2 4.1 (2.2) 2.5 (1.8) 4.4 (1.4) 4.0 (2.5) 5.6 91.9) <0.001
Day 3 3.0 (1.9) 1.6 (1.6) 3.2 (1.2) 3.0 (2.2) 4.4 (1.7) <0.001
Day 4 2.4 (1.9) 1.3 (1.5) 2.4 (1.6) 2.5 (1.9) 3.6 (1.7) 0.001
Day 5 1.9 (2.0) 0.9 (1.4) 2.1 (1.8) 2.4 (2.5) 2.7 (1.9) 0.013
Day 6 1.6 (1.9) 0.5 (0.8) 1.8 (1.8) 2.0 (2.5) 2.1 (1.9) 0.014
Day 7 1.3 (1.8) 0.3 (2.5) 1.5 (1.5) 1.6 (2.5) 1.8 (1.8) 0.006
Table 3. Postoperative VAS score based on endoscopic urological surgery
Postoperative TURP URS/Lithotripsy DJ Stent Removal/Cystoscopy P
Day 1 6.9 (2.5) 5.1 (2.4) 4.5 (2.6) 0.014
Day 2 4.7 (2.2) 4.4 (2.3) 3.4 (2.0) 0.134
Day 3 3.5 (1.8) 3.3 (1.9) 2.4 (1.9) 0.162
Day 4 2.4 (1.4) 2.8 (1.9) 1.9 (1.9) 0.241
Day 5 2.0 (1.7) 2.3 (2.2) 1.6 (1.9) 0.318
Day 6 1.8 (1.6) 1.8 (2.1) 1.2 (2.0) 0.242
Day 7 1.1 (1.4) 1.5 (1.8) 1.2 (2.0) 0.566
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Table 4. Most frequent adverse events and patient complaints
Overall Pipemidic Acid Phenazopyridine HCl
Sodium 
diclofenac Placebo
Additional analgetic, n (%) 11 (13.8) 1 (5) 3 (15) 3 (15) 4 (20)
Fever, n (%) 5 (6.3) 1 (5) 1 (5) 1 (5) 2 (10)
Nausea, n (%) 24 (30) 4 (20) 6 (30) 6 (30) 8 (40)
Vomitus, n (%) 6 (7.5) 0 (0) 1 (5) 2 (10) 3 (15)
Abdominal discomfort, n (%) 14 (17.5) 0 (0) 4 (20) 3 (15) 7 (35)
Skin rash, n (%) 1 (1.3) 0 (0) 0 (0) 0 (0) 1 (5)
Table 5. Post hoc analysis
P value for VAS Score
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Pipemidic acid
Phenazopyridine HCl <0.001 0.001 0.003 0.031 0.017 0.011 0.002
Sodium Diclofenac 0.01 0.046 0.036 0.039 0.018 0.023 0.042
Placebo <0.001 <0.001 <0.001 <0.001 0.002 0.001 0.001
Phenazopyridine 
HCl
Sodium Diclofenac 0.415 0.592 0.782 1 0.923 0.966 0.53
Placebo 0.198 0.044 0.012 0.022 0.275 0.526 0.571






Figure 1. Pain scale changes on the Visual Analog Scale (VAS) – (p<0.05)
urological surgery. The goal of pain management 
after endoscopic treatments is to relieve pain 
and, keep the side effects to a minimum at the 
same time.17
Pain induced by endoscopic treatments is not 
the result of tissue injury alone and indeed has no 
significant effect. Cystoscopy usually causes pain 
due to preoperative anxiety and postoperative 
patients often suffer a urinary tract irritation 
following surgery.4 However, in TUR-P, the 
resected adenoma cannot be rationally associated 
with pain induction, since the major causes of 
TUR-P pain are bladder spasms, catheter-related 
pain and capsule offense.1,6 An in-dwelling 
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urinary catheter is a foreign body positioned in 
the bladder and can often cause severe pain and 
discomfort and impair the quality of life of the 
patient. The presence of a urinary catheter can 
trigger the bladder muscle to go into spasm in 
an effort to expel the catheter. This spasm leads 
to cramping lower abdominal pain.
The placement of ureteral stent following 
ureteroscopy remains a common practice. Stents 
have been routinely placed to facilitate passage 
of residual stone fragments, prevent ureteral 
stricture formation and renal colic secondary 
to ureteral edema. Unfortunately, ureteral 
stenting continues to result in significant patient 
morbidity, including flank pain, lower abdominal 
or loin discomfort, urinary urgency, urinary 
frequency, hematuria, infection, encrustation and 
migration. It has been reported that 38% to 80% 
of patients experience stent-related symptoms. 
To address this problem, modifications in 
ureteral stent design have been used, including 
self-retaining designs, softer biomaterials, dual 
durometer stents, reduced caliber configurations, 
biostable materials and biodegradable stents.18 
Postoperative ureteral stent discomfort may be 
resolved by these modifications.6
Current approaches for the management 
of catheterization/ureteral, stent-related pain/
discomfort include the use of non-steroidal 
anti-inflammatory medications, oral narcotics, 
oral anticholinergic medications (oxybutynin 
or tolterodine), drug-eluting/coated stents, and/
or oral local anesthetics (phenazopyridine). The 
efficacy of these medications in the treatment 
of pain/discomfort needs to be clarified and 
they are prescribed based mainly on intuition 
and assumption of good clinical practice.18 
The analgesic effect of pipemidic acid still 
requires further clarification and remains a 
controversial matter. No study to date has 
compared the analgesic effect of pipemidic 
acid, phenazopyridin and NSAID following 
endoscopic urological treatments.
The clinical indication of phenazopyridine 
remains unclear. It has been used clinically in 
conditions with increased bladder sensation, such 
as cystitis and bladder pain syndrome/interstitial 
cystitis. Phenazopyridine (2,6-diamino-3-
[phenyl-azo]pyridine) hydrochloride has been 
used clinically as a local anesthetic/analgesic 
to provide symptomatic relief of pain in certain 
conditions, such as cystitis and urethritis. In 
addition, this drug is being used as a therapeutic 
option in patients with chronic bladder pain 
syndrome/interstitial cystitis (BPS/IC), and 
also hydrodistention, amitriptyline or pentosan 
polysulfate sodium. But there is little information 
available to date on the mode of action of the 
drug, i.e. influence to the sensory mechanisms, 
which have been referred to in the afferent 
functions in the rat.19 Phenazopyridine HCl is 
effective for early acute pain relief following 
cystoscopy4, management of postoperative 
ureteral stent discomfort,6,18 and catheterization 
discomfort.6
NSAIDs for analgesia after surgery is a 
controversial matter, due to increased risk of 
post-operative bleeding by inhibition of the 
other isoforms of cyclo-oxygenase, causing anti-
platelet activity.1 Diclofenac sodium is an NSAID. 
NSAIDs are effective analgesics without the 
undesirable side effects associated with opioids, 
such as sedation, respiratory depression, nausea 
and vomiting. They inhibit the synthesis and the 
release of prostaglandins at the site of surgical 
trauma by inhibition of cyclo-oxygenase-2 
(COX-2), which responsible for pain, fever and 
vasodilatation in response to trauma.17 NSAIDs 
are known to decrease the incidence of bladder 
spasms through the reduction of the amount of 
prostaglandins released. Moreover, NSAIDs 
may help reduce postoperative edema, resulting 
in successful early catheter removal.1 In a 
further study, non-steroidal anti-inflammatory 
drugs have demonstrated strong antimicrobial 
properties when tested against a large number 
of gram-positive and gram-negative bacteria. 
The MIC range was from 50-200 Ìg/mL in most 
of the cases and recorded even lower in some 
instances. Diclofenac is suggested to possess the 
capacity to treat urinary tract infections caused 
by drug-resistant E. coli strains.20
Pipemidic acid (HPPA),  8-ethyl-5, 
8-dihydro-5-oxo-2-(1-piperazinyl)-pyrido[2,3-d]
pyrimidine-6- carboxylic acid, is a therapeutic 
agent for urinary tract infections due to its 
antibacterial activity against gram-negative, 
and some gram-positive bacteria.7,8,10,11,13,21 The 
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analgesic effect of pipemidic acid remains unclear 
and association with optimalization of pipemidic 
acid autotaxin inhibitor has been reported.12 
The ectoenzyme autotaxin (ATX) possesses 
lysophospholipase D phosphodiesterase and, 
to a lesser extent, nucleotide pyrophosphatase 
activities. In 1992, the ATX protein was purified 
and characterized from melanoma cell-conditioned 
medium, after which it was assigned to the 
nucleotide pyrophosphatase phosphodiesterase 
subfamily of alkaline phosphatases based on 
sequence homology.22 Subsequently, ATX was 
shown to be the lysophospholipase D enzyme 
responsible for synthesis of the bioactive lipid 
lysophosphatidic acid (LPA) in vivo.12
Recent work has shown that ATX plays 
a critical role in normal human development 
and disease. ATX has been linked to cancer 
progression, multiple sclerosis, obesity, diabetes, 
Alzheimer’s disease and chronic pain through 
the production of LPA.12,22 One study reports a 
convenient diversification strategy to generate 
structure-activity relationship (SAR) data in 
the hope of better understanding ATX inhibitor 
recognition, and in identifying more potent 
analogs. In this study, the derivatization of 
pipemidic acid with commercially available 
isothiocyanate building blocks was identified 
as a facile route to a range of analogs of 
compound 1 bearing various substituents on the 
phenylthiourea motif.12
Lysophosphatidylcholine (LPC, lysolecithin) 
is an important cell signaling molecule among 
lysophospholipids. It is a major plasma lipid 
component that transports fatty acids and choline 
to tissues, and is produced under physiological 
and pathological conditions.14 Recent reports 
suggest that LPC modulates pain signaling. 
LPC treatment of the aphenous or sciatic nerve–
induced neuropathic pain, such as mechanical 
allodynia and thermal hyperalgesia, as well as 
demyelination and up-regulation of pain-related 
proteins in the dorsal root ganglion (DRG). 
However, the molecular mechanisms underlying 
LPC-induced neuropathic pain-like symptoms 
remain to be determined.15 More recently, a 
study reported that intrathecal (i.t.) injection of 
lysophosphatidic acid (LPA) induces mechanical 
allodynia and thermal hyperalgesia, as well as 
demyelination of dorsal root and upregulation 
of pain-related proteins in the DRG and spinal 
cord via the LPA1 receptor.14 Autotaxin (ATX), 
is responsible for the conversion of LPC to 
LPA, and is abundantly expressed in central 
and peripheral nerve tissues, especially in 
cerebrospinal fluids.14,15,23
This study had several limitations. First, 
this study had fewer sample in randomization 
and the study population was limited in rural 
hospital in Central Java. Further research is 
necessary to develop medications, improve 
design or modifications in surgical techniques 
that may effectively treat and/or prevent pain-
related endoscopic treatment. This investigation 
provides a sound foundation for future studies to 
assess the ability of oral agents to reduce pain 
following endoscopic urological surgery.
CONCLUSION
The study suggests that pipemidic acid, 
phenazopyridine HCl and sodium diclofenac, 
as oral analgesics, have been proven effective 
for pain relief following endoscopic urological 
surgery without inducing any side effects. 
Pipemidic acid has been found to have more 
superior analgesic effect than phenazopyridine 
HCl and sodium diclofenac.
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